

**Table 1.9a**  
**Immunosuppression Use by Organ in 2006 and 2007**

	Organ								
	Heart-Lung	Heart	Intest-ine	Kidney	KP	Liver	Lung	PAK	PTA
<b>Transplants (2007)</b>	29	2,207	198	16,623	862	6,489	1,471	261	208
<b>Tx With Immunosuppression Info at Discharge</b>	27	2,135	194	16,114	840	6,207	1,404	247	197
<b>Induction Drug Reported</b>	81.5%	53.9%	49.0%	78.0%	78.0%	25.8%	62.3%	80.2%	67.0%
<b>Induction Drugs</b>									
Atgam/NRATG/NRATS	33.3%	4.2%	0.5%	1.1%	1.8%	1.2%	5.8%	1.2%	1.0%
OKT3	7.4%	3.2%	17.5%	1.2%	1.2%	2.9%	1.0%	0.4%	7.6%
Thymoglobulin	0.0%	19.2%	23.7%	43.8%	52.0%	9.6%	4.3%	61.9%	42.1%
Zenapax	11.1%	12.7%	9.8%	10.8%	6.5%	8.2%	16.2%	2.0%	7.1%
Simulect	25.9%	14.2%	2.1%	16.6%	5.7%	5.6%	25.9%	4.0%	3.6%
Campath	18.5%	2.6%	13.4%	9.5%	13.2%	1.4%	9.8%	12.1%	13.7%
<b>Tx With Immunosuppression Info and Functioning Graft at Discharge</b>	26	2,044	166	15,884	826	5,902	1,325	228	182
<b>Maintenance at Discharge</b>									
Corticosteroids Use	100.0%	88.7%	77.1%	65.9%	65.4%	75.9%	95.3%	58.3%	58.2%
Steroids	100.0%	88.7%	77.1%	65.9%	65.4%	75.9%	95.3%	58.3%	58.2%
Calcineurin Inhibitor Use	100.0%	97.9%	97.0%	95.6%	98.3%	97.9%	97.6%	97.8%	97.3%
Cyclosporine	3.8%	33.0%	0.0%	10.1%	4.5%	7.2%	10.1%	4.8%	2.2%
Tacrolimus	96.2%	64.9%	97.0%	85.4%	93.8%	90.7%	87.5%	93.0%	95.1%
Antimetabolite Use	84.6%	91.9%	22.9%	92.1%	91.2%	72.8%	92.2%	94.3%	59.3%
Mycophenolate Mofetil	65.4%	85.6%	21.1%	75.0%	73.2%	67.2%	54.3%	83.8%	52.2%
Mycophenolate Sodium	3.8%	3.4%	0.0%	16.4%	17.2%	4.9%	6.4%	9.2%	5.5%
Azathioprine	15.4%	2.8%	1.8%	0.6%	0.7%	0.6%	31.5%	1.3%	1.6%
Leflunomide	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%
mTOR Inhibitor Use	0.0%	4.5%	9.0%	5.2%	10.5%	2.5%	0.2%	7.9%	17.0%
Sirolimus	0.0%	1.2%	9.0%	4.8%	10.5%	2.5%	0.2%	7.9%	17.0%
Everolimus	0.0%	3.3%	0.0%	0.4%	0.0%	0.0%	0.0%	0.0%	0.0%
<b>Transplants (2006)</b>	31	2,193	175	17,091	924	6,650	1,406	293	173
<b>Tx With Maintenance Use at 1yr PostTx</b>	20	1,879	120	15,092	803	5,245	1,141	218	122
<b>Maintenance at 1yr PostTx</b>									
Corticosteroids Use	100.0%	68.4%	60.8%	65.8%	67.6%	39.6%	97.4%	67.4%	48.4%
Steroids	100.0%	68.4%	60.8%	65.8%	67.6%	39.6%	97.4%	67.4%	48.4%
Calcineurin Inhibitor Use	95.0%	96.5%	99.2%	91.7%	96.4%	92.7%	96.8%	95.0%	99.2%
Cyclosporine	5.0%	32.0%	1.7%	11.2%	6.2%	8.3%	11.2%	6.9%	2.5%
Tacrolimus	90.0%	64.5%	97.5%	80.6%	90.2%	84.5%	85.5%	88.1%	96.7%
Antimetabolite Use	85.0%	87.1%	6.7%	86.7%	83.8%	49.3%	84.6%	83.0%	50.0%
Mycophenolate Mofetil	60.0%	76.7%	5.8%	67.7%	57.7%	44.1%	51.3%	67.4%	35.2%
Mycophenolate Sodium	0.0%	5.1%	0.0%	16.9%	24.4%	4.7%	4.6%	13.3%	13.9%
Azathioprine	25.0%	5.2%	0.8%	1.4%	1.0%	0.6%	28.7%	1.4%	0.8%
Leflunomide	0.0%	0.2%	0.0%	0.8%	0.7%	0.0%	0.0%	0.9%	0.0%
mTOR Inhibitor Use	0.0%	9.3%	12.5%	11.3%	16.1%	9.4%	6.1%	16.1%	22.1%
Sirolimus	0.0%	7.6%	12.5%	10.8%	16.1%	9.4%	6.1%	16.1%	22.1%
Everolimus	0.0%	1.6%	0.0%	0.5%	0.0%	0.0%	0.0%	0.0%	0.0%

Source: OPTN/SRTR Data as of May 1, 2008.

## Notes:

Individual drug percentages will not necessarily add up to the drug category percentages, as patients may be prescribed more than one drug within the same category. Induction drugs include any reported antilymphocyte antibodies and antibodies directed against lymphocyte receptors.